Codexis (CDXS) Projected to Post Earnings on Thursday
Codexis (NASDAQ:CDXS) is projected to announce its Q4 2025 earnings before market open on Thursday, February 26th, with analysts forecasting EPS of $0.01 and revenue of $35.834 million. The biotechnology company will host an earnings call on Friday, February 27th at 4:00 PM ET. CDXS shares opened at $1.17, with a market capitalization of $105.67 million, and currently hold a "Sell" rating from Wall Street analysts.
Codexis to Participate in TD Cowen 46th Annual Health Care Conference
Codexis, Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2-4, 2026, in Boston, Massachusetts. Management will host a fireside chat on March 3, 2026, at 11:50 am ET, with a live webcast and replay available on the company's investor relations website. Codexis develops enzymatic solutions for therapeutic manufacturing using its CodeEvolver® technology platform.
Codexis to Participate in TD Cowen 46th Annual Health Care Conference
Codexis, Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2-4, 2026, in Boston, Massachusetts. Management will engage in a fireside chat on March 3, 2026. A live webcast and archived replay will be available on the company's Investor Relations website.
Codexis to Participate in TD Cowen 46th Annual Health Care Conference
Codexis, Inc. (NASDAQ: CDXS) announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2-4, 2026. Management will host a fireside chat on March 3, 2026, at 11:50 am ET, with a live webcast available on the company's investor relations website. The company specializes in enzymatic solutions for manufacturing complex therapeutics and is developing its ECO Synthesis® platform for RNAi therapeutics.
Positive Sentiment Still Eludes Codexis, Inc. (NASDAQ:CDXS) Following 29% Share Price Slump
Codexis, Inc. (NASDAQ:CDXS) has seen its share price drop by 29% in the last month and 71% over the past year, leading to a low price-to-sales (P/S) ratio of 2x, which is lower than many peers in the Life Sciences industry. Despite recent revenue decline, analysts project strong future growth of 32% per year for the next three years, significantly outpacing the industry forecast of 7.7%. The low P/S ratio suggests investors might be skeptical of these growth forecasts or perceive underlying risks, even though price risks appear minimal.
Positive Sentiment Still Eludes Codexis, Inc. (NASDAQ:CDXS) Following 29% Share Price Slump
Codexis, Inc. (NASDAQ:CDXS) has experienced a 29% share price drop in the last month and a 71% decline over the past year, leading to a low price-to-sales (P/S) ratio of 2x. Despite its revenue decreasing by 18% in the last year, analysts forecast a 32% annual revenue growth for the next three years, significantly higher than the industry average. The low P/S ratio, despite strong growth forecasts, suggests investor skepticism regarding potential risks and future revenue volatility.
Codexis Achieves ISO 9001:2015 Certification
Codexis Inc. announced it has achieved ISO 9001:2015 certification for its Redwood City headquarters, recognizing its commitment to quality assurance across all operations, including R&D, manufacturing, and customer service. This certification validates the company's robust quality management system and its dedication to continuous improvement to deliver high-quality enzymatic solutions for therapeutics manufacturing. The company highlighted that this achievement reflects a collective commitment to excellence by all its employees.
Codexis (CDXS) Achieves ISO 9001:2015 Certification
Codexis Inc (CDXS) has successfully attained ISO 9001:2015 certification, demonstrating its commitment to quality assurance across all operations, from R&D to customer service, for its enzymatic solutions in therapeutics manufacturing. Despite this achievement, the company faces significant financial challenges including negative operating and net margins, declining revenue growth, and a high debt-to-equity ratio, leading to a precarious Altman Z-Score. While the company exhibits strong liquidity, market sentiment and analyst recommendations suggest caution, highlighting risks associated with its financial health and stock volatility.
Codexis Inc. Achieves ISO 9001:2015 Certification for Quality Management Excellence
Codexis Inc. has achieved ISO 9001:2015 certification, demonstrating its commitment to high-quality manufacturing practices across research, product development, and customer service. This certification reinforces the company's dedication to quality assurance and operational excellence, particularly for its enzymatic solutions used in therapeutics manufacturing. The company also reported Q3 2025 revenues of $8.6M, a decrease from the prior year, and recent insider selling activity.
What Codexis’ new ISO 9001 status means for enzyme buyers
Codexis Inc. announced it achieved ISO 9001:2015 certification on February 10, 2026, for its Redwood City headquarters, R&D labs, and non-GMP manufacturing facility. This certification signifies the company's commitment to quality management in the design, development, manufacturing, delivery, and support of its biomanufacturing products and services. The market reacted positively to the news, with Codexis stock (CDXS) gaining 5.59%.
Biofuel Enzymes Market Set to Soar: Innovations Driving Cleaner, Efficient Energy Solutions by 2032 | Major Companies - AB Enzymes GmbH, Codexis Inc., Logen Corporation, Royal DSM NV.
The Global Biofuel Enzymes Market is projected to grow at a CAGR of 6.4% during 2024-2031, driven by increasing demand for renewable fuels, technological advancements, and environmental regulations. Recent developments in the US and Japan highlight significant investments and innovations in enzyme technology to improve biofuel efficiency and cost-effectiveness. Key players in this market include AB Enzymes GmbH, Codexis Inc., and Royal DSM NV, among others.
New partnership tests greener way to mass-produce RNA medicines
Codexis (CDXS) announced an evaluation agreement with Axolabs to test its ECO Synthesis Manufacturing Platform for enzymatic RNA/oligonucleotide production. This collaboration aims to advance efficient and sustainable manufacturing of oligonucleotide therapeutics, potentially leading to future licensing and broader adoption of the platform. The partnership reinforces both companies' commitment to expanding access to high-quality oligonucleotide-based medicines.
Codexis CSO Stefan Lutz sells $7949 in shares By Investing.com
Codexis, Inc.'s Chief Scientific Officer, Stefan Lutz, sold 4,685 shares of the company's common stock for $7,949 on January 7, 2026, to cover tax liabilities from restricted stock unit vesting. Following the sale, Lutz directly owns 138,775 shares. This transaction comes as Codexis, an enzyme engineering company, faces financial challenges, having reported Q3 2025 revenue and EPS below expectations, though its stock saw a slight increase in after-hours trading.
Codexis CSO Stefan Lutz sells $7949 in shares By Investing.com
Codexis (NASDAQ: CDXS) Chief Scientific Officer Stefan Lutz sold 4,685 shares of common stock for $7,949 on January 7, 2026, to cover tax liabilities from restricted stock unit vesting. The transaction occurred amidst financial challenges for the company, which reported lower-than-expected Q3 2025 revenue and EPS. Despite the financial headwinds, InvestingPro data suggests Codexis may be undervalued.
Codexis CSO Stefan Lutz sells $7949 in shares
Codexis Chief Scientific Officer Stefan Lutz sold 4,685 shares of common stock for $7,949 on January 7, 2026, primarily to cover tax liabilities from restricted stock units. This transaction occurred as the company, with a $152 million market capitalization, faces financial challenges and is considered undervalued by InvestingPro data. Codexis recently reported a significant revenue and EPS miss for Q3 2025, though its stock saw a slight increase in after-hours trading.
Codexis CSO Stefan Lutz sells $7949 in shares
Codexis Chief Scientific Officer Stefan Lutz sold 4,685 shares of the company's common stock for $7,949 to cover tax liabilities from restricted stock unit vesting. Following the transaction, Lutz directly owns 138,775 shares. This sale comes as Codexis faces financial challenges, as highlighted by its recent Q3 2025 earnings report which showed revenues and EPS significantly below forecasts.
Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics
Codexis and Axolabs have signed an evaluation agreement for Codexis' ECO Synthesis Manufacturing Platform, aiming to improve the efficiency and scalability of oligonucleotide therapeutics manufacturing. This partnership grants Axolabs access to an innovative RNA manufacturing solution powered by enzymatic synthesis, paving the way for potential future licensing and broader adoption of the platform. Both companies highlight their commitment to advancing the science and accessibility of high-quality oligonucleotide-based medicines globally.
Enzyme Engineering Market Set for Rapid Growth and Trend
The Global Enzyme Engineering Market is projected to grow significantly from USD 8.63 Billion in 2025 to USD 16.29 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.5%. This growth is driven by rapid innovation, increasing investments, and evolving regional dynamics. The market study offers insights into segmentation by type, application, and region, along with detailed profiles of key players like Novozymes A/S and DuPont de Nemours Inc.
Opaleye Management Inc. Reduces Stake in Codexis Inc.
Opaleye Management Inc. significantly reduced its stake in Codexis Inc. by 1,063,221 shares, a decrease of 8.31%, at a price of $1.76 per share. This strategic move leaves Opaleye with 11,731,779 shares in Codexis, representing 12.99% of its holdings in the company. The decision reflects a cautious approach by Opaleye given Codexis Inc.'s ongoing financial challenges and poor future performance potential, despite its modestly undervalued stock price.
Opaleye management sells Codexis (CDXS) shares for $1.87 million
Opaleye Management Inc., a major shareholder in Codexis, Inc. (NASDAQ:CDXS), sold shares worth $1.87 million in multiple transactions from November 7 to November 11, 2025. These sales occurred at prices between $1.6968 and $1.7994 per share. Following these transactions, Opaleye L.P. directly holds 11,508,318 shares.
Opaleye management sells Codexis (CDXS) shares for $1.87 million By Investing.com
Opaleye Management Inc., a major shareholder in Codexis, Inc. (NASDAQ:CDXS), sold $1.87 million worth of shares through multiple transactions between November 7 and November 11, 2025. These sales occurred at prices ranging from $1.6968 to $1.7994 per share. This divestment follows a challenging quarter for Codexis, which reported an $8.6 million revenue, significantly missing analyst expectations of $18.66 million, and a deeper-than-anticipated EPS loss of $0.22.
Codexis Featured in CBS’s Economy 4.0 Docuseries Highlighting RNA Manufacturing Innovation
Codexis, a leader in enzymatic technology, is featured in CBS’s Economy 4.0 docuseries for its ECO Synthesis Manufacturing Platform. This platform, which utilizes advanced enzyme engineering and AI, addresses the growing global demand for RNA therapeutics by providing a more scalable and environmentally friendly production method than traditional chemical techniques. The innovation aims to increase patient access to life-saving RNA-based therapies.
Codexis Featured in CBS’s Economy 4.0 Docuseries Highlighting RNA Manufacturing Innovation
Codexis will be featured in CBS’s Economy 4.0 docuseries, showcasing its ECO Synthesis Manufacturing Platform for enzymatic RNA. This platform addresses the increasing demand for RNA by providing higher quality and improved scalability for RNA production, crucial for manufacturing RNA-based therapies. The technology leverages advanced enzyme engineering and AI to create high-quality RNA efficiently and with reduced environmental impact.
Codexis Featured in CBS’s Economy 4.0 Docuseries Highlighting RNA Manufacturing Innovation
Codexis, a leader in enzymatic technology, is being featured in CBS's Economy 4.0 docuseries for its ECO Synthesis Manufacturing Platform, which innovates RNA production. This platform aims to scale RNA therapeutics to meet growing global demand by offering a more efficient, high-quality, and environmentally friendly manufacturing approach compared to traditional methods. CEO Alison Moore emphasizes that this technology is crucial for increasing patient access to life-saving RNA-based medicines.
Codexis Featured in CBS’s Economy 4.0 Docuseries Highlighting RNA Manufacturing Innovation
Codexis is being featured in CBS's Economy 4.0 docuseries to showcase its ECO Synthesis® Manufacturing Platform, which innovates the production of RNA. This platform leverages enzymatic technology to provide higher quality and more scalable RNA manufacturing, addressing the growing global demand for RNA therapeutics. The process also reduces environmental impact by avoiding harsh organic solvents, making critical RNA-based therapies more accessible to patients.
IP;Codexis' ECO Synthesis® Manufacturing Platform: Transforming RNA Therapeutics
Codexis' ECO Synthesis® Manufacturing Platform offers a breakthrough enzymatic approach to RNA production, addressing the limitations of traditional synthesis methods. This platform leverages engineered enzymes for high-fidelity, low-waste manufacturing, enabling scalable and sustainable production of RNA therapeutics. By doing so, Codexis aims to facilitate the widespread availability of life-changing treatments for various conditions, bridging the gap between scientific discovery and patient access.
Opaleye Management Inc. Reduces Stake in Codexis Inc.
Opaleye Management Inc. has reduced its stake in Codexis Inc. by selling 514,341 shares at $1.71 each, impacting its portfolio by -0.13%. This transaction leaves Opaleye Management with 10,134,989 shares, representing 11.23% of its portfolio in Codexis. The move is seen as a strategic decision given Codexis's current financial challenges, including negative growth in key performance metrics, despite the stock being considered modestly undervalued with a GF Value of $2.15.
Codexis' ECO Synthesis® Manufacturing Platform: Transforming RNA Therapeutics
Codexis is addressing the manufacturing bottleneck in RNA therapeutics with its ECO Synthesis® Manufacturing Platform, an enzymatic approach designed for scalable, sustainable production. This platform leverages engineered enzymes to replace traditional, resource-intensive methods, making RNA therapies more accessible for a range of conditions like diabetes, cardiovascular disease, and cancer. Codexis's expertise in biocatalysis positions it as a leader in bridging the gap between RNA discovery and broad patient delivery.
Codexis, Inc. Signs $37.8 Million Supply Assurance Agreement with Merck, Announces Leadership Changes and Cost Reductions to Extend Cash Runway Through 2027
Codexis, Inc. has secured a $37.8 million Supply Assurance Agreement with Merck, significantly boosting its financial stability and extending its cash runway through 2027. This proactive move is accompanied by substantial organizational changes, including a 24% workforce reduction and a leadership transition with Alison Moore succeeding Stephen Dilly as CEO, all aimed at streamlining operations and focusing on future growth in oligonucleotide manufacturing despite a reported Q3 2025 net loss of $19.6 million.
Codexis, Inc. Leases New GMP Manufacturing Facility in Hayward, California to Expand siRNA Production Capabilities
Codexis, Inc. announced it has leased a 34,000 square foot GMP manufacturing facility in Hayward, California, to expand its siRNA and oligonucleotide production capabilities using its ECO Synthesis platform. Modifications to the facility will begin in early 2026, aiming to support customers in early clinical trials and enhance the company's role in enzymatic manufacturing. This move underscores Codexis's commitment to innovation in RNA therapeutics and positions it as a key development partner.
Codexis Announces Signing of Lease for GMP Manufacturing Facility
Codexis, Inc. has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California. This facility will allow Codexis to expand into GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform, supporting early clinical trials. The company anticipates beginning modifications in early 2026, pivoting its strategy to become a key development partner for enzymatic oligonucleotide manufacturing.
Codexis switches CEOs as it lays off workers and grabs manufacturing space in East Bay
Biotech firm Codexis has appointed Alison Moore as its new CEO, while concurrently laying off 24% of its workforce. The company is also expanding its operations by leasing new manufacturing space in the East Bay and has secured a significant deal with drugmaker Merck.
Earnings call transcript: Codexis Q3 2025 results reveal revenue shortfall
Codexis reported Q3 2025 revenues of $8.6 million, significantly missing the $18.66 million forecast, and an EPS loss of $0.22, deeper than the anticipated $0.15 loss. This led to a 5.35% stock price drop. The company is strategically shifting its focus from traditional enzyme development to oligonucleotide manufacturing, particularly siRNA therapeutics, and expects to meet or exceed its 2025 revenue guidance despite the current shortfall. CEO Stephen Dilly is transitioning to Executive Chair, with CTO Alison Moore set to become the new CEO.
Codexis Inc reports results for the quarter ended September 30 - Earnings Summary
Codexis Inc (CDXS) reported an adjusted loss of 22 cents per share for the quarter ended September 30, missing analyst expectations of a 15-cent loss. Revenue also significantly fell by 33% to $8.60 million against an expected $18.51 million. Despite this, the average analyst rating for CDXS shares is a "buy" with a median 12-month price target notably above its last closing price.
Better than natural: next-generation therapeutics through advanced protein engineering
This article showcases Codexis's advanced protein engineering platform, CodeEvolver, for developing next-generation therapeutics. The company uses directed evolution and AI to create optimized protein and gene therapies, addressing limitations of natural proteins in treating diseases like PKU and Fabry disease. Codexis's technology also extends to improving components of gene therapies and has a strong history of industrial biocatalysis.
Codexis, Inc. to Report Third Quarter 2025 Financial Results on November 6
Codexis, Inc. announced its plan to release its Q3 2025 financial results on November 6, 2025, after market close, followed by a conference call and webcast at 4:30 PM ET. The company, a leader in enzymatic solutions for therapeutic manufacturing, will discuss its financial performance and provide a business update. The article also details recent insider trading activity and institutional holdings for Codexis (CDXS).
Codexis to Report Third Quarter 2025 Financial Results on November 6
Codexis, Inc. announced it will report its financial results for the third quarter of 2025 on Thursday, November 6, 2025, after market close. The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss results and provide a business update, accessible through their investor relations website.
Codexis to Report Third Quarter 2025 Financial Results on November 6
Codexis, Inc. announced it will report its third-quarter 2025 financial results on Thursday, November 6, 2025, after market close. Management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the results and provide a business update. The webcast will be archived on the Codexis Investor Relations website, and a telephone replay will also be available.
Codexis (CDXS) chief technical officer Moore sells $15,629 in stock By Investing.com - Investing.com Nigeria
The article reports that Codexis (CDXS) Chief Technical Officer, Moore, sold $15,629 worth of company stock. This transaction is categorized under insider trading news. The full details of this sale would typically be provided in the body of a complete article.
Codexis (CDXS) chief technical officer Moore sells $15,629 in stock By Investing.com - Investing.com South Africa
The Chief Technical Officer of Codexis (CDXS), Dr. Robyn R. Moore, sold 2,246 shares of the company's common stock at an average price of $6.96 per share, totaling approximately $15,629. This transaction was disclosed in a recent SEC filing and occurred on June 3, 2024. Following the sale, Moore directly owns 72,131 shares of Codexis stock.
Codexis CFO Erbez sells $15,628 in shares By Investing.com - Investing.com Nigeria
The article reports on Codexis CFO Erbez selling $15,628 worth of shares. It also flags a Q3 Earnings Alert for upcoming stock reports. The main content of the article, however, seems to be experiencing an application error.
Codexis CFO Erbez sells $15,628 in shares - Investing.com
This article reports that Codexis CFO Erbez sold $15,628 worth of shares. The article's content is minimal due to an application error, but highlights this insider transaction.
Codexis (CDXS) chief technical officer Moore sells $15,629 in stock - Investing.com India
This article reports that Codexis's Chief Technical Officer, Moore, sold $15,629 worth of company stock. The article headline is the only substantive content available, as the body of the article presents an application error.
Codexis CFO Erbez sells $15,628 in shares - Investing.com India
This article reports that Codexis CFO, Erbez, sold shares worth $15,628. Unfortunately, the full content of the article is unavailable due to an application error on the Investing.com India website.
Codexis (CDXS) chief technical officer Moore sells $15,629 in stock - Investing.com
Codexis, Inc.'s Chief Technical Officer, Alison Moore, sold 6,239 shares of company stock for $15,629 to cover tax obligations related to restricted stock units. This sale occurred while CDXS stock trades between its 52-week range of $1.90 to $6.08. The company recently reported strong Q2 2025 financial results, including increased revenue and a reduced net loss, leading to reiterated 'Buy' and 'Overweight' ratings from some analysts, despite a 'Hold' from another.
Investors in Codexis (NASDAQ:CDXS) have unfortunately lost 79% over the last five years
Codexis (NASDAQ:CDXS) shareholders have experienced a significant 79% loss over the past five years, with an average annual decline of 12%, while also seeing a 15% drop over the last year. This underperformance is attributed to the company being unprofitable and experiencing a 6.3% annual reduction in trailing twelve-month revenue. The article suggests focusing on revenue and revenue growth for unprofitable companies, and it advises caution due to declining revenues and the absence of insider buying.
Codexis Reports Second Quarter 2025 Financial Results
Codexis, Inc. announced its financial results for the second quarter ended June 30, 2025, reporting total revenues of $15.3 million, exceeding analyst consensus. The company highlighted strong performance in its Pharma Biocatalysis business and significant progress with its ECO Synthesis® platform, including external validation from CDMO collaborators. Codexis also strengthened its cash position by raising $27.3 million to support the expansion of its ECO Synthesis platform and its path to GMP-grade siRNA.
Top 5 Synthetic Biology Public Companies (February 2026)
This article identifies and details the top five publicly traded synthetic biology companies as of February 2026, based on their track record of innovation, product development, and potential for commercialization. The author provides an overview of synthetic biology, explaining its distinction from genome editing, and then presents an analysis of each selected company: Twist Bioscience, Ginkgo Bioworks, Precigen, Codexis, and LanzaTech Global, highlighting their unique technologies and market positions. The article also offers guidance for investors looking to build a synthetic biology portfolio, emphasizing diversification, risk management, and the importance of monitoring scientific and commercial developments in this rapidly evolving field.
Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Codexis (NASDAQ:CDXS) missed its first-quarter earnings and revenue expectations, reporting US$7.5m in revenue, significantly below forecasts. Despite the miss, analysts have slightly updated their sentiment, lowering the predicted loss per share for 2025 by 5.4% to US$0.69, while revenue forecasts remained steady at US$65.5m. The company is expected to significantly increase its revenue growth in the future compared to its past performance, exceeding industry averages, though there's a wide range in analyst price targets.
Earnings call transcript: Codexis Q1 2025 results miss forecasts, stock declines
Codexis Inc. reported a significant miss in its Q1 2025 earnings, with EPS of -$0.25 against a forecast of -$0.24, and revenue of $7.5 million compared to an expected $10.32 million, leading to a 10.16% stock decline in aftermarket trading. Despite the financial setback, the company highlighted an improved product gross margin to 55% and the launch of a new machine learning tool for RNA fragment design, maintaining its 2025 revenue guidance between $64 million and $68 million. Executives emphasized a focus on execution and the potential for their ECO synthesis platform to drive future growth, particularly in RNA-based therapeutics, with strong interest from CDMOs.
